I had a meeting with the Chief Exec of the UK’s premier cancer research hospital, last year. He was genuinely interested by my pitch about LLLT. He said I should meet his pain team to present data on Oral Mucositis (OM). Eventually a meeting was set and I gave my best to the Head of Pain Services. Lets call him Dr Fred. Dr Fred listened patiently then, when I had finished, he gave me some feedback: 1) he did not like the company logo 2) he accepts the mechanism of action but 3) LLLT achieves too many things and 4) he had to go to another meeting. A surgeon friend of mine offered to go persuade Dr Fred and they had two hour meeting. Dr Fred said he would pitch it to his team, but after a few weeks chasing for an update, he said that nobody was interested.
How can that be when (according to the article in this months literature watch by Rene-Jean Bensadoun and Raj Nair) there is no consensus on a single agent or agents that can be used either prophylactically or therapeutically to reduce severity or duration of oral mucositis, and yet four associations/agencies* either suggest or recommend LLLT for OM.
Could it be the case that they did not discover LLLT for OM so they are not interested? The good news is that there are three cancer hospitals in three different countries coordinating to run a multi centred trial with THOR lasers so maybe then we can get some interest.
* European Society for Medical Oncology, Multinational Association of Supportive Care in Cancer, International Society of Oral Oncology, U.S. Dept of Health and Human Services Agency for Healthcare Research and quality.
Tell me about your experience, leave a comment below.